MAEA and cancer: An AXL-targeting antibody–drug, Enapotamab vedotin (EnaV), effectively enhances ICB benefit in human BLM melanoma and lung LCLC-103H cancer models [252].These results unveiled a potentially promising combination therapy, which synergistically targets EMP via extracellular inducers and their transmembrane receptors.